Rafeh Naqash, Abdul, et al. “Interleukin-6 As One of the Potential Mediators of Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Blockade: Evidence from a Case Report”. Acta Oncologica, vol. 57, no. 5, May 2018, pp. 705-8, doi:10.1080/0284186X.2017.1406668.